Sujatha Gurunathan

Blog Post

Muscular Dystrophy Association Awards 18 Grants Totaling Over $1.6 Million for Neuromuscular Disease Research

By Sujatha Gurunathan | November 5, 2021
Blog Post

Research Study Alert: Observational Study of Clinical and Electrophysiological Outcomes in Adults with CMT

By Sujatha Gurunathan | October 11, 2021
Blog Post

Clinical Trial Alert: Phase 3b Study of Oral Edaravone in Adults with ALS

By Sujatha Gurunathan | October 11, 2021
Blog Post

Capricor Announces Positive Results from its Phase 2 Study of CAP-1002 to Treat DMD

By Sujatha Gurunathan | September 30, 2021
Blog Post

FDA approves Octapharma’s Octagam® 10% for Treatment of Adults with Dermatomyositis

By Sujatha Gurunathan | July 29, 2021
Blog Post

Biogen’s Early Access Program for Tofersen is Now Open for Individuals with Rapidly Progressing SOD1-ALS

By Sujatha Gurunathan | July 6, 2021
Blog Post

FDA Approves Sarepta Therapeutics’ Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45

By Sujatha Gurunathan | February 25, 2021
Blog Post

How Expedited Drug Approval Impacts the Neuromuscular Disease Treatment Landscape

By Sujatha Gurunathan | February 4, 2021
Blog Post

Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatments

By Sujatha Gurunathan | November 17, 2020
Blog Post

Scholar Rock Announces Positive Results from Interim Analysis of TOPAZ Phase 2 Study of SRK-015 to Treat SMA

By Sujatha Gurunathan | October 28, 2020